However, participants reached a consensus of agreement on prescribing SGLT2 inhibitors to people with type 2 diabetes (regardless of ulceration status) with concurrent heart failure and/or chronic kidney disease, regardless of glycaemic control status. The gene discussed is SLC5A2; the disease is chronic kidney disease.